Intellia Therapeutics, Inc. $NTLA Shares Sold by Trexquant Investment LP

Key Points

• Trexquant Investment LP has reduced its stake in Intellia Therapeutics, selling 62,936 shares to own 604,696 shares, now valued at approximately $4.3 million.
• Voloridge Investment Management significantly increased its stake by 226.8%, while Two Sigma Advisers and Two Sigma Investments also made substantial enhancements to their holdings in Intellia Therapeutics.
• Analysts have mixed ratings on Intellia, with a recent consensus rating of "Moderate Buy" and a target price of around $29.05 despite some analysts lowering their price objectives.

Trexquant Investment LP cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 9.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 604,696 shares of the company's stock after selling 62,936 shares during the quarter. Trexquant Investment LP owned 0.58% of Intellia Therapeutics worth $4,299,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of NTLA. GF Fund Management CO. LTD. purchased a new stake in shares of Intellia Therapeutics in the fourth quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after buying an additional 1,655 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock valued at $37,000 after buying an additional 2,264 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of Intellia Therapeutics by 846.4% in the first quarter. Quantbot Technologies LP now owns 6,663 shares of the company's stock valued at $47,000 after buying an additional 5,959 shares in the last quarter. Finally, 49 Wealth Management LLC purchased a new stake in shares of Intellia Therapeutics in the first quarter valued at approximately $74,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NTLA has been the topic of a number of analyst reports. Wells Fargo & Company restated an "overweight" rating and issued a $45.00 price target (down from $50.00) on shares of Intellia Therapeutics in a research note on Friday, August 8th. Canaccord Genuity Group reduced their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a report on Tuesday, June 3rd. HC Wainwright decreased their target price on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Royal Bank Of Canada decreased their target price on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Finally, Chardan Capital decreased their target price on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Twelve analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.05.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 7,462 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William J. Chase bought 100,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the purchase, the director directly owned 134,693 shares of the company's stock, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their position. The disclosure for this purchase can be found here. Insiders sold 12,534 shares of company stock worth $153,837 over the last 90 days. Company insiders own 3.10% of the company's stock.

Intellia Therapeutics Trading Down 0.8%

Shares of NASDAQ:NTLA traded down $0.09 on Thursday, hitting $11.62. The company had a trading volume of 2,967,974 shares, compared to its average volume of 4,080,202. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $23.76. The business has a 50 day moving average of $11.40 and a 200 day moving average of $9.61. The company has a market cap of $1.25 billion, a PE ratio of -2.48 and a beta of 2.28.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. During the same period in the prior year, the business earned ($1.52) earnings per share. The business's revenue was up 104.3% on a year-over-year basis. As a group, equities analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.